LuciSora — Sorafenib 200 mg, 120 pcs, Lucius

LuciSora — Sorafenib Tablets 200 mg, 120 Tablets

Product code: 514

5364₴ 5856₴ -8% On order · from 10 days

Analogues

1
Active ingredient
Dosage
200 mg
Dosage form Tablets
Tablets per pack 120

LuciSora is an established targeted antineoplastic agent belonging to the multi-kinase inhibitor class, indicated for the treatment of renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer. The active pharmaceutical ingredient is sorafenib at a strength of 200 mg supplied as film-coated oral tablets (Sorafenib Tablets 200 mg). The product is developed and manufactured by Lucius Pharmaceuticals.

Sorafenib is an oral multi-kinase inhibitor that blocks tumor cell proliferation and suppresses angiogenesis (the formation of new blood vessels supplying the tumor). It inhibits cell-surface kinases (such as VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-beta) and intracellular kinases (Raf-1, BRAF, and mutant BRAF variants). Through its dual mechanism of action (antitumor and anti-angiogenic), the drug effectively halts tumor growth across various oncological pathologies.

Supplied in a package containing 120 tablets of 200 mg. Intended exclusively for oral administration under the strict supervision of an oncologist.

Key Clinical Features and Advantages of LuciSora 200 mg:

  • ✅ Multi-Targeted Action: Simultaneous inhibition of VEGF, PDGF, and RAF pathways to suppress tumor growth and vascular network development.
  • ✅ Broad Indication Spectrum: Proven efficacy in liver, kidney, and thyroid cancers.
  • ✅ Convenient Strength: 200 mg tablets optimal for precise dosing regimen compliance.
  • ✅ Oral Dosing: Taken orally twice daily.
  • ✅ Lucius Pharmaceuticals Standards: High-quality, accessible generic alternative to the originator product (Nexavar).

LuciSora is supplied as film-coated tablets for oral administration.

Qualitative and Quantitative Composition per Tablet:

  • Active Ingredient: Sorafenib (as sorafenib tosylate) — 200 mg (equivalent to 200 mg sorafenib).
  • Excipients: Croscarmellose sodium, microcrystalline cellulose, hypromellose, sodium lauryl sulfate, magnesium stearate. Coating: hypromellose, macrogol, titanium dioxide, iron oxide red.

Packaging and Presentation: Film-coated tablets, 200 mg strength. Each package contains 120 tablets along with prescribing information. Labeled with LuciSora (Sorafenib Tablets 200 mg) and Lucius Pharmaceuticals corporate graphics.

Pharmacodynamics:
Sorafenib is a kinase inhibitor with antiproliferative and anti-angiogenic activity. It suppresses serine/threonine kinases (C-Raf, B-Raf, and mutant V600E BRAF variants) and receptor tyrosine kinases involved in angiogenesis (VEGFR-2, VEGFR-3, PDGFR-beta). Inhibition of these signaling pathways leads to decreased tumor blood supply and triggers cancer cell apoptosis.

Pharmacokinetics:

  • Absorption: Following oral administration, sorafenib absorption is moderate; absolute bioavailability is approximately 38% to 49%. Peak plasma concentration (Tmax) is achieved within approximately 3 hours. High-fat meals reduce drug bioavailability.
  • Distribution: Human plasma protein binding is very high (approx. 99.5%).
  • Metabolism: Extensively metabolized in the liver, primarily via CYP3A4 enzyme of the cytochrome P450 system and glucuronidation (UGT1A9).
  • Elimination: Excreted predominantly via feces (approx. 77% as metabolites) and renally (approx. 19%). Terminal elimination half-life (T1/2) averages approximately 25 to 48 hours.

LuciSora is indicated in adult patients for:

  • Hepatocellular Carcinoma: Treatment of patients with unresectable liver cancer.
  • Renal Cell Carcinoma: Treatment of patients with advanced renal cell carcinoma failing prior therapy or as first-line treatment.
  • Thyroid Cancer: Treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

LuciSora is administered orally twice daily every day.

Dosing Regimen:
The recommended standard dose is 400 mg (two 200 mg tablets) twice daily (total daily dose of 800 mg). Continue treatment as long as clinical benefit is observed or until unacceptable toxicity occurs.

Administration Guidelines:
Tablets should be taken on an empty stomach or with a moderate-fat, light meal (avoid high-fat meals) with a glass of water. Tablets must be swallowed whole; do not break or crush. If dose reduction is necessary, decrease to 400 mg once daily or 200 mg twice daily.

Administration of LuciSora is contraindicated in:

  • Hypersensitivity: Known hypersensitivity to sorafenib or any excipient.
  • Pregnancy and Lactation: Strictly contraindicated in pregnant or breastfeeding women.
  • Pediatric Population: Safety and efficacy in patients under 18 years have not been established.
  • Squamous Cell Lung Cancer: Combination with certain platinum-based chemotherapy regimens in squamous cell lung cancer.

Sorafenib is metabolized in the liver via CYP3A4 and UGT1A9:

  • Strong CYP3A4 Inducers (rifampicin, dexamethasone, phenytoin, carbamazepine, St. John's Wort): Significantly decrease sorafenib plasma concentrations and reduce efficacy (avoid concurrent use).
  • CYP3A4 Inhibitors (ketoconazole, itraconazole): Exert minimal impact on sorafenib pharmacokinetics.
  • CYP2B6, CYP2C8, and CYP2C9 Substrates: Sorafenib may inhibit these enzymes, increasing concentrations of co-administered drugs.

Pregnancy:
LuciSora is contraindicated during pregnancy. Based on its mechanism of action, sorafenib may cause severe developmental birth defects and embryotoxicity. Females of reproductive potential and male partners must utilize effective reliable contraception during treatment and for at least 6 months following the final dose.

Lactation:
Excretion of sorafenib into human breast milk is unstudied, though potentially hazardous to the child. Breastfeeding must be discontinued during treatment.

The most frequent and clinically significant adverse reactions include:

  • Dermatologic Reactions (Very Common): Palmar-plantar erythrodysesthesia (hand-foot syndrome), rash, alopecia, dry skin, pruritus.
  • Cardiovascular System: Arterial hypertension (regular blood pressure monitoring required), ischemic heart disease.
  • Gastrointestinal Tract: Diarrhea, nausea, vomiting, abdominal pain, stomatitis, decreased appetite.
  • General Disorders: Fatigue, asthenia, weight loss, hemorrhage.
  • Laboratory Abnormalities: Elevations in lipase and amylase, hypophosphatemia, increased liver transaminases, thrombocytopenia.

Symptoms:
Specific acute overdose symptoms of sorafenib are unestablished. The most frequent manifestations upon overdose are diarrhea and dermatologic reactions (hand-foot syndrome).

Treatment:
No specific antidote exists. In case of suspected overdose, temporarily discontinue treatment and initiate supportive and symptomatic care under medical supervision.

Storage Requirements for LuciSora 200 mg:

  • 🌡️ Temperature Range: Store in original packaging in a dry place protected from light at temperatures below 30 °C.
  • 👶 Safety Precautions: Keep strictly out of reach of children (cytotoxic antineoplastic agent).
  • ⏳ Shelf Life: Stated on carton and blister pack. Don't use past expiration date. Prescription-only oncology medicine.

To verify authenticity of genuine LuciSora 200 mg manufactured by Lucius Pharmaceuticals, inspect the following security and visual features:

  • ✅ Security Hologram & Scratch Code: Outer carton features an official Lucius Pharmaceuticals anti-counterfeit holographic seal with a scratch-off verification code for online validation via the manufacturer's official portal.
  • ✅ Corporate Branding: High-resolution printing displaying Lucius Pharmaceuticals graphics, Sorafenib Tablets 200 mg, and 120 Tablets count.
  • ✅ Factory Markings: Clearly printed Batch No., Mfg. Date, and Exp. Date matching across outer packaging and internal blister packs.
  • ✅ Prescribing Information: Includes an official product leaflet inside the outer carton.
On order · from 10 days
100% original product
Delivery across Ukraine
1

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 17.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00